Four-gene expression ratio test for survival in patients undergoing surgery for mesothelioma

Journal of the National Cancer Institute

Volumn 101, Issue 9, 2009, Pages 678-686

  Gordon, Gavin J ^a   Dong, Lingsheng ^a   Yeap, Beow Y ^c   Richards, William G ^a   Glickman, Jonathan N ^b   Edenfield, Heather ^a   Mani, Madhubalan ^a   Colquitt, Richard ^a   Maulik, Gautam ^a   Van Oss, Branden ^a   Sugarbaker, David J ^a   Bueno, Raphael ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARHGDIA GENE; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; COBLL1 GENE; CYTOREDUCTIVE SURGERY; FEMALE; GENE; GENE EXPRESSION; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; PKM2 GENE; PLEURA BIOPSY; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS; REPRODUCIBILITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TM4SF1 GENE; ANALYSIS OF VARIANCE; CANCER STAGING; CHEMISTRY; DNA MICROARRAY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; MESOTHELIOMA; MIDDLE AGED; MORTALITY; PATHOLOGY; PLEURA TUMOR; PREDICTION AND FORECASTING; RISK;

MEMBRANE ANTIGEN; PYRUVATE KINASE; TM4SF1 PROTEIN, HUMAN; TUMOR MARKER; TUMOR PROTEIN;

ADULT; AGED; ANALYSIS OF VARIANCE; ANTIGENS, SURFACE; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MESOTHELIOMA; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM STAGING; ODDS RATIO; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PLEURAL NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; PYRUVATE KINASE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR MARKERS, BIOLOGICAL;

EID: 65549156408     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djp061     Document Type: Article

References (33)

1. Chang MY, Sugarbaker DJ. Extrapleural pneumonectomy for diffuse malignant pleural mesothelioma: techniques and complications. Thorac Surg Clin.2004;14(4):523-530.
2. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pem- etrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol.2003;21(14):2636-2644.
3. Sugarbaker D, Strauss GM, Lynch TJ, et al. Node status has prognostic significance in the multimodality therapy of diffuse, malignant mesothelioma. J Clin Oncol.1993;11(6):1172-1178.
4. Sugarbaker DJ, Flores RM, Jaklitsch MT, et al. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg.1999; 117(1):54-65.
5. Quackenbush J. Weighing our measures of gene expression [published online ahead of print November 14, 2006]. Mol Syst Biol.2006;2:63. doi:10.1038/msb4100096.
6. Quackenbush J. Computational approaches to analysis of DNA microarray data. Methods Inf Med.2006;45(suppl 1):91-103.
7. Quackenbush J. Microarray analysis and tumor classification. N Engl J Med.2006;354(23):2463-2472.
8. Quackenbush J. Standardizing the standards. Mol Syst Biol.2006;2:2006 0010.
9. Chen HY, Yu SL, Chen CH, et al. A five-gene signature and clinical outcome in non-small-cell lung cancer. N Engl J Med.2007;356(1):11-20.
10. Chung CH, Bernard PS, Perou CM. Molecular portraits and the family tree of cancer. Nat Genet.2002;32(suppl):533-540.
11. van 't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature.2002;415(6871):530- 536.
12. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med.2004; 351(27):2817-2826.
13. van de Vijver MJ, He YD, van't Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med.2002;347(25):1999-2009.
14. Sotiriou C, Piccart MJ. Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care? Nat Rev Cancer.2007;7(7):545-553.
15. Bueno R, Loughlin KR, Powell MH, Gordon GJ. A diagnostic test for prostate cancer from gene expression profiling data. J Urol.2004; 171 (2 Pt 1):903-906.
16. Gordon GJ, Jensen RV, Hsiao LL, et al. Using gene expression ratios to predict outcome among patients with mesothelioma. J Natl Cancer Inst.2003;95(8):598-605.
17. Gordon GJ, Jensen RV, Hsiao L-L, et al. Translation of microarray data into clinically relevant cancer diagnostic tests using gene expression ratios in lung cancer and mesothelioma. Cancer Res.2002;62(17):4963-4967.
18. Gordon GJ, Richards WG, Sugarbaker DJ, Jaklitsch MT, Bueno R. A prognostic test for adenocarcinoma of the lung from gene expression profiling data. Cancer EpidemiolBiomarkers Prev.2003;12:905-910.
19. Gordon GJ, Rockwell GN, Godfrey PA, et al. Validation of genomics- based prognostic tests in malignant pleural mesothelioma. Clin Cancer Res.2005;11(12):4406-4414.
20. Gordon GJ, Rockwell GN, Jensen RV, et al. Identification of novel candidate oncogenes and tumor suppressors in malignant pleural mesothelioma using large-scale transcriptional profiling. Am J Pathol.2005;166(6): 1827-1840.
21. Richards W, Van Oss S, Glickman J, et al. A microaliquoting technique for precise histological annotation and optimization of cell content in frozen tissue specimens. Biotech Histochem.2007;82(4&5):189-197.
22. Aalen O. Nonparametric estimation of partial transition probabilities in multiple decrement models. Ann Stat.1978;6(3):534-545.
23. Gray R. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat.1988;16(3):1141-1154.
24. Grambsch P, Therneau T. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika.1994;81(3):512-526.
25. Bueno R, Reblando J, Glickman J, Jaklitsch MT, Lukanich JM, Sugarbaker DJ. Pleural biopsy: a reliable method for determining the diagnosis but not subtype in mesothelioma. Ann Thorac Surg.2004;78(5):1774-1776.
26. Stevens CW, Forster KM, Smythe WR, Rice D. Radiotherapy for mesothelioma. Hematol Oncol Clin North Am.2005;19(6):1099-1115.
27. Flores RM, Pass HI, Seshan VE, et al. Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients [published online ahead of print February 14, 2008]. J Thorac Cardiovasc Surg.2008;135:620-626, 626.e1-3.
28. Flores RM, Zakowski M, Venkatraman E, et al. Prognostic factors in the treatment of malignant pleural mesothelioma at a large tertiary referral center. J Thorac Oncol.2007;2(10):957-965.
29. Sugarbaker DJ. Macroscopic complete resection: the goal of primary surgery in multimodality therapy for pleural mesothelioma. J Thorac Oncol.2006;1(2):175-176.
30. Richards WG, Zellos L, Bueno R, et al. Phase I to II study of pleurectomy/decortication and intraoperative intracavitary hyperthermic cisplatin lavage for mesothelioma. J Clin Oncol.2006;24(10):1561-1567.
31. Golub TR, Slonim DK, Tamayo P, et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science.1999;286(5439):531-537.
32. Quackenbush J. Computational analysis of microarray data. Nat Rev Genet.2001;2(6):418-427.
33. Marchionni L, Wilson RF, Wolff AC, et al. Systematic review: gene expression profiling assays in early-stage breast cancer [published online ahead of print February 4, 2008]. Ann Intern Med.2008;148(5):358-369.